UroGen Pharma Ltd (URGN)
Healthcare
Biotechnology
38.20 $
-6.9%
vs. previous close
Closing price · As of: 31. Jul 2026
UroGen Pharma Ltd (URGN) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Operating Cash Flow" came in at -162 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
| Tick rows to compare them in a chart (up to 4) | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -4.1 | -7.2 | 4.2 | -9.6 | -37 | -71 | -106 | -85 | -88 | -76 | -97 | -162 | |
| 0.0 | 0.1 | 0.2 | 0.2 | 0.4 | 1.3 | 2.0 | 1.8 | 1.8 | 1.7 | 1.2 | 2.4 | |
| 0.3 | 0.4 | 2.0 | 6.3 | 31 | 30 | 28 | 23 | 11 | 9.3 | 13 | 12 | |
| 0.3 | 4.8 | 4.7 | 6.5 | 31 | 30 | 27 | 23 | 11 | – | – | – | |
| -0.2 | 0.6 | 1.2 | 3.8 | 7.2 | 4.3 | -6.4 | -13 | -6.3 | 3.3 | 4.9 | -28 | |
| 0.0 | 0.3 | 0.7 | 0.3 | 0.6 | 0.3 | 1.2 | 0.8 | 0.3 | 0.2 | 0.3 | 0.3 | |
| 0.0 | -0.3 | -0.8 | -36 | 35 | -146 | 93 | 4.1 | 1.1 | -1.0 | -21 | 62 | |
| 61 | 22 | 0.6 | 62 | 67 | 165 | 17 | -0.1 | 1.4 | – | – | – | |
| 0.6 | – | – | – | -0.2 | – | 0.1 | 0.0 | 96 | 0.0 | 24 | -1.9 | |
| 5.0 | 22 | 0.0 | 62 | 66 | 165 | 17 | 72 | 97 | 117 | 195 | 40 | |
| 0.8 | 14 | 3.4 | 16 | 64 | -51 | 3.9 | -8.5 | 11 | 40 | 77 | -61 | |
| -4.1 | -7.5 | 3.5 | -9.8 | -38 | -71 | -107 | -86 | -88 | -77 | -97 | -163 |
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.